Sign in
DRUG Stock Price, Chart, Stats & News
Bright Minds Biosciences Inc.
Save
510.63M
Market cap
–
Current P/E
–
Forward P/E
DRUG chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.84% |
ROE | -28.46% |
D/E | 0.00x |
Interest coverage ratio | – |
DRUG valuation
P/E | – |
P/S | – |
P/B | 8.46x |
P/CF | -58.05x |
P/FCF | -58.06x |
P/OCF | -58.05x |
PEG | 0.50x |
EV multiple | -44.11x |
About
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome.
Similar securities
Based on sector and market capitalization
Report issue